Navigation Links
GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines
Date:10/23/2008

VIENNA, Austria, October 23 /PRNewswire/ -- GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by targeting beta-amyloid.

As part of the agreement GSK is acquiring exclusive rights to develop and commercialise two Alzheimer's disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and are currently in Phase I clinical development. AFFiRiS is also granting GSK an exclusive option to develop and commercialise alternative Alzheimer's disease vaccine candidates which are in preclinical development.

Under the terms of the agreement, AFFiRiS will receive an up-front payment of EUR 22.5 million (GBP17.5 million) and could be eligible for future milestone payments and royalties. The total potential value of the agreement could reach EUR 430 million (GBP334 million) in the event of full commercial success of the candidate vaccines. This agreement is subject to governmental authority approval.

Central to the deal is the AFFiRiS AFFiTOPE technology which allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing "rogue" human proteins such as beta-amyloid which is central to the pathology of Alzheimer's disease.

Commenting on the agreement, Walter Schmidt, co-founder and CEO of AFFiRiS, stated: "We are pleased that we could secure GSK Biologicals, one of the world's leading vaccine companies, in collaborating on the development our Alzheimer's disease vaccine programs. This deal brings together two companies with strong innovation, vaccine development and commercialisation capabilities and experience."

Jean Stephenne, President and General Manager of GlaxoSmithKline Biologicals, said "We are impressed with the AFFiRiS technology - combined with our expe
'/>"/>

SOURCE AFFiRiS GmbH, GlaxoSmithKline Biologicals (GSKBiologicals)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
2. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
3. GlaxoSmithKline To Post Quarterly US Grants Report
4. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
5. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
6. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
7. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
8. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
9. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
10. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015   Intrexon Corporation (NYSE: ... announced today the appointment of Olivier R. ... Sector.  Mr. Jarry will lead the expansion of ... applications for consumer markets.  Mr. ... experience in leading global life sciences and consumer ...
(Date:6/2/2015)... Cord Blood Corporation (NYSE: CO ) ("CCBC," the "Company," ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... Special Committee of the Company,s board of directors (the "Special ... ) Limited as its independent financial advisor, Cleary ... United States legal counsel and Maples & Calder ...
(Date:6/2/2015)... AZ (PRWEB) June 02, 2015 Through ... microscope technology, Yancy Corporation is enabling World ... desired material and biological sample, displaying the full nature ... bonds between atoms. , Jeff Porter, Co-Founder of the ... are just that – rare. They come once in ...
(Date:6/2/2015)... Orleans, LA (PRWEB) June 02, 2015 ... custom gene synthesis to improve protein expression, announced the ... board includes six executives and entrepreneurs with a broad ... software industries. , The team includes: , Jimmy ... Fund: , Roussel has a background in technology and ...
Breaking Biology Technology:Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3
... the Project on Emerging Nanotechnologies (PEN) at the ... variety of voluntary options available for the oversight ... Voluntary Initiatives, Regulation, and Nanotechnology Oversight: Charting a ... Center for Environmental Policy at American University, provides ...
... today released the first in a series of video ... technology correspondent Miles O,Brien and currently airing nationally on ... quick look at what happens when genius meets possibility: ... shaping our world. The 26-part video series is ...
... ... if ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s ... (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Biology Technology:OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9OncoGenex Reports Third Quarter Financial Results 10OncoGenex Reports Third Quarter Financial Results 11OncoGenex Reports Third Quarter Financial Results 12OncoGenex Reports Third Quarter Financial Results 13
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... drug delivery methods that are more effective and less ... Chemists at The University of Nottingham are developing new ... do not damage the latest generation of delicate biopharmaceutical ... medical treatment. Conventional methods of coating drugs can ...
... Conservation International (CI) today announced a partnership with ... more than 4,000 acres of the Philippines Peablanca ... Northeastern part of one of the nations main ... local communities will receive additional benefits from agroforestry ...
... unresolved as to whether the Neanderthals died out ... of deteriorating climatic conditions. Although scientists have gained ... difficult to pinpoint the climatic character at the ... by an international team of researchers, published this ...
Cached Biology News:Using green chemistry to deliver cutting-edge drugs 2Using green chemistry to deliver cutting-edge drugs 3Using green chemistry to deliver cutting-edge drugs 4Conservation International and Toyota partner to protect Philippines' rain forests 2Conservation International and Toyota partner to protect Philippines' rain forests 3Climate -- no smoking gun for Neanderthals 2
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Phospho-FADD (Ser194) Antibody (Human Specific)...
... polyclonal to FANCM ( Abpromise for ... Synthetic peptide derived from within residues ... (Note: the amino acid sequence is ... ab27787 .) Entrez ...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: